Trials / Completed
CompletedNCT02647333
Intervention With Omega Fatty Acids in High-risk Patients
Intervention With Omega Fatty Acids in High-risk Patients With Hypertriglyceridemic Waist
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Haukeland University Hospital · Academic / Other
- Sex
- All
- Age
- 30 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
In order to reduce cardiovascular risk, current European guidelines recommend a diet low on saturated fatty acid through replacement with polyunsaturated fatty acids (PUFA). Polyunsaturated fatty acids can be classified into omega-3 and omega-6. However the results from recent meta-analyses investigating coronary risk outcomes did not clearly support a low intake of saturated fatty acids and a high intake of omega-3 or omega-6. The aim of this study is to investigate the short term effects of a high intake of PUFAs on microvascular function, lipids, inflammation and other cardiovascular risk factors in inactive patients with increased waistline.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Omega-3 Fatty Acid | Experimental: Omega-3 fatty acid In the intervention period the participants will receive a daily supplement of omega-3 fatty acids for 8 weeks, where the dosage are 3 and 4 g/day for women and men, respectively. The omega-3 supplement is a hydrolyzed and reesterified TAG fish oil, containing 33 area percent eicosapentaenoic acid and 22 area percent docosahexaenoic acid. |
| DIETARY_SUPPLEMENT | Omega-6 Fatty Acid | Experimental: Omega-6 fatty acid In the intervention period the participants will receive a daily supplement of omega-6 fatty acid for 8 weeks, where the dosage are 20 and 27 g/day for women and men, respectively. The omega-6 supplement is a high-quality organic, cold pressed and filtered safflower oil, containing 68-83% linoleic acid, 5-15% saturated fatty acid, 8-21% oleic acid, 0,0-0,5% ALA and maximum 2% other fatty acids. |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2016-04-01
- Completion
- 2016-04-01
- First posted
- 2016-01-06
- Last updated
- 2016-12-20
Source: ClinicalTrials.gov record NCT02647333. Inclusion in this directory is not an endorsement.